Evaluation of Miricorilant on Liver Fat in Patients With MASLD
← catalyst calendarNCT06947304 · readout ≤ 12 d
Sponsored by Corcept Therapeutics (industry) · CORT — their whole pipeline →. With University of Missouri-Columbia.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
9actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-22 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Nonalcoholic Steatohepatitis (NASH)
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Non-alcoholic Fatty Liver Disease (NAFLD)
Intervention
- Drug: Miricorilant
Primary outcomes
what the primary-completion date above is the date OFChange in fasting hepatic lipogenesis after 6 weeks of treatment
measured Baseline to Week 6
Change in peak lipogenesis after 6 weeks of treatment.
measured Baseline to Week 6
Permalink · CORT's whole pipeline · Catalyst calendar · Every registered study · What changed